Mobile Health

Mobile Health solutions are a key driver to digital health and are transforming healthcare.

Consumers want to take responsibility and control of their own health and the Affordable Care Act is providing economic incentives which are pushing healthcare from the hospital. Powerful physiologic sensors integrated with smart phones enable this revolution. LifeWave Biomedical’s UWB physiologic sensors are wireless and wearable and optimized for particular applications.

LifeWave Biomedical’s UWB physiologic sensors are easily implemented are small, wireless and wearable. These innovations can sense a diverse set of physiologic parameters thus enabling the diagnosis and treatment of a large number of medical conditions outside of the clinic. Acquired physiologic data is continuously and wirelessly uploaded to the cloud enabling physicians direct connectivity to monitor their patients’ health seamlessly. This low-cost sensor technology facilitates physiologic data parallelization between all care settings and mobile settings.

Applications

Third Trimester Maternal Fetal Monitor

There is an unmet nascent need for expectant mothers to assess the health and wellbeing of their unborn baby and to be alerted to potential distress in the third-trimester. While a fetal distress diagnostic is not practical, an “assurance” monitor is practical in assessing fetal heart rate, contractions, and fetal movements/kicks. Mothers can be provided the information to make their own evaluation of potentially non-reassuring data so that they may contact their physician for evaluation and a clinical non-stress test.

LifeWave Biomedical's first product will be the FitBaby™, a third-trimester wearable maternal-fetal monitor that will have the following capabilities:

  1. Provide an anytime/anywhere wearable (sensor & app) that enhances a mother’s emotional connectivity to her unborn baby.
  2. Provide data that can be easily shared with her family and is particularly effective in involving her partner in her pregnancy experience.
  3. Provide data and tools that provide fetal well-being assurance to the mother.
  4. Provide data and tools that permit a mother to share useful data with her clinicians, not for the purpose of clinical diagnosis, but for more complete communication and timely action so that a clinical diagnosis can be made in a clinical facility.

The FitBaby can be expected to have FDA approval and be available for consumer purchase on-line and at retail channels. The FitBaby™ is designed to improve a mother’s connection to her unborn baby by providing feedback on the baby’s activity and data to provide assurance of the baby’s well being. The baby's fetal heart rate and fetal kicks are assessed and transferred to a smartphone for display, storage, alerts, and sharing. The product will also measure uterine contractions and similar to the baby’s well-being data, the uterine contraction data is transferred to the smartphone for display, storage, alerts, and sharing. Heart rate variability, from the baby’s baseline, during periods of the baby’s activity or during uterine contractions may be observed and if non-reassuring, the mother may contact her physician.

Fetal kicks are indicative of an unborn babies health and kick counting is now being recognized as the first proactive strategy to help reduce a baby’s risk of stillbirth. It is recommended that during the last trimester, a woman perform a kick count at the same time every day when the baby is most active. This establishes a record of activity that may be characterized and plotted and enables a woman to observe variability and a potential problem.

The FitBaby™ works through clothing or against the skin. The device may be used discretely for 24/7 monitoring or for periodic monitoring during the day when the baby is most active or when the woman may be experiencing contractions late in her third term. The device is very small, fits in the palm on the hand and is approximately 2" x 3" x 0.5".

Respiration Monitoring

Respiration monitoring is crucial in the acute care and in-hospital setting as life-threatening events are frequently preceded by irregularities in respiration. Symptoms of respiratory distress can include shortness of breath, labored breathing and excessive accessory muscle use. Since many diverse medical conditions affect the lungs and overall pulmonary function, acquiring accurate respiratory data can provide information on the diagnosis and progression of a disease or injury. Although, different methods exist to monitor pulmonary or respiratory functionality, they are complex, inconvenient, limited in their scope or too expensive. Furthermore, they lack the ability to be used in an ambulatory setting and require the patient to be monitored in the clinic or hospital.

A simple, reliable and portable device to simultaneously sense respiratory information and cardiac information is invaluable to society and can satisfy the unmet needs in healthcare today. Providing this critical information will allow healthcare provider to provide appropriate care in a timely fashion. Furthermore, a truly ambulatory device will enable healthcare providers unique insight into a person’s pulmonary responses to stresses in everyday life. LifeWave’s unique UWB radar physiologic sensing technology can be implemented in both the clinic and mobile respiration monitoring systems with its ability to measure lung wall motion, respiratory rate and rhythm, inspiration and exhalation times and detect asymmetrical respiration due to inflammation or obstructions.

COPD

Chronic Obstructive Pulmonary Disease (COPD) is the fourth largest cause of death in the United States and contributes to 700,000 hospitalizations annually. According to the World Health Organization, it will become the third leading cause of death worldwide by 2030. COPD refers to those conditions which cause decreased air flow in the lungs. The airflow limitation is progressive and associated with an abnormal inflammatory response of the lungs. Typically, COPD is diagnosed using a spirometer to measure air flow and volume but is not able to assess individual lung lobe functionality. Ventilators, used in the ICU and the operating room can provide valuable data about air flow, lung volume and pressures, but require the patient to be intubated and under sedation or general anesthesia.

LifeWave Biomedical’s unique UWB physiologic sensing technology can be implemented in both clinical and mobile respiratory monitoring systems. Its ability to measure lung wall motion, respiratory rate and rhythm, inspiration and exhalation times and asymmetrical respiration due to inflammation or obstructions is an invaluable tool to diagnose COPD as well as for ongoing treatment management.

CPR

Cardiopulmonary Resuscitation (CPR)’s efficacy is elusive in that a mere 4-20% of adults receiving CPR are successfully resuscitated. Two primary components of CPR are chest compressions and then evaluating the effects of those compressions. Assessing the effectiveness of CPR is an essential tool for Emergency Medical Technicians (EMT). Assessing the effectiveness of Cardiopulmonary Resuscitation is an essential tool for Emergency Medical Technicians (EMT) but current methods to assess the timing and depth of compressions are subjective, time-consuming and sensitive to motion.

To address this critical need, LifeWave Biomedical has developed a miniature Ultra-Wide Band (UWB) Radio Frequency (RF) medical radar for managing the application of CPR and assisting with cardiac resuscitation. We have developed signal processing algorithms that operate on UWB radar data collected from a patient’s chest. These specific algorithms analyze heart wall motion and changes in the chest cavity geometry to provide actionable information concerning the presence or absence of viable blood flow as well as feedback on the application of CPR.

Furthermore, LifeWave Biomedical’s UWB radar technology can be implemented as a stand-alone device or incorporated with a defibrillator. Thus, the administrator of CPR can be informed of the depth of compressions and when critical blood pressure has been restored which provides indication of the return of spontaneous circulation (ROSC).

Sleep Apnea

Sleep apnea affects more than 18 million Americans. At least 2% of women and 4% of men have sleep apnea but most cases go undiagnosed. LifeWave Biomedical’s UWB radar technology can be applied to assess cardiopulmonary activity and respiration patterns. This, combined with a blood oxygen sensor, provides patients with a simple in home sleep apnea test. Diagnosed sufferers of sleep apnea can continue to have respiration assessed at home to determine the effectiveness of prescribed treatments. Treatments can then be tailored to a person’s specific respiration and sleep habits for a personalized healthcare approach to sleep apnea.